Six‐month clinical follow‐up of the tryton side branch stent for the treatment of bifurcation lesions

Magro, Michael; Wykrzykowska, Joanna J.; Serruys, Patrick W.; Şimşek, Cihan; Nauta, Sjoerd T.; Lesiak, Maciej; Stanisławska, Katarzyna; Onuma, Yoshinobu; Regar, Evelyn; Domburg, Ron T. van; Grajek, Stefan; Geuns, Robert‐Jan van

doi:10.1002/ccd.22767

Cited by 31 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Tryton stent is one such dedicated bifurcation device, which is used in combination with a work-horse DES, and could therefore be considered a two-stent technique. Two clinical studies on this device have been previously published: a First-In-Man (FIM) study and a two-centre registry [5,24]. Compared with these two previously published clinical studies on the Tryton stent, the current study showed slightly better clinical outcomes concerning MI (FIM 6.6 %, twocentre registry 3 %), comparable outcomes on TLR (FIM 6.6 %, two-centre registry 4 %), and stent thrombosis (no stent thrombosis in either the FIM or the twocentre registry), and slightly worse outcomes on cardiac deaths (FIM 3.3 %, two-centre registry 1 %).…”

Section: Discussionmentioning

confidence: 99%

“…The Tryton stent could potentially optimise side branch ostium scaffolding, while minimising the amount of metal in the main branch [4]. A previous twocentre registry has shown promising procedural and clinical outcomes after placement of this dedicated device [5]. To confirm these observations, we investigated procedural success and clinical outcomes after treatment of BLs with the Tryton stent in 91 consecutive patients treated for BLs in our own centre.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

et al. 2012

View full text Add to dashboard Cite

Aims Percutaneous coronary intervention (PCI) of a bifurcation lesion (BL) is still associated with poorer clinical outcomes when compared with PCI of a non-BL. Therefore, several dedicated coronary bifurcation stents, such as the Tryton Side Branch Stent™ (Tryton Medical, Durham, NC, USA), were developed to improve clinical outcomes. We investigated 6-month clinical outcomes after placement of a Tryton stent in 91 patients treated for 93 BLs in our centre. Methods and results All consecutive patients who have undergone PCI of a BL treated with the Tryton stent in our centre were included. Outcomes were defined as any death, cardiac death, myocardial infarction (MI), any revascularisation, ischaemia-driven target vessel revascularisation (TVR), ischaemia-driven target lesion revascularisation (TLR), stent thrombosis, and target vessel failure (TVF; composite of cardiac death, MI, and ischaemia-driven TVR). Event rates were estimated using the Kaplan-Meier method. Thirty-eight (42 %) patients with acute coronary syndrome (ACS) were included (16 % ST-segment elevation MI (STEMI)). The 6-month event rates were 5.4 % (death), 4.3 % (cardiac death), 2.2 % (MI), 4.5 % (any revascularisation), 4.5 % (TVR), 4.5 % (TLR) and 9.7 % (TVF). ConclusionIn a real-world all-comers single-centre registry, the use of the Tryton Side Branch Stent was associated with acceptable procedural and promising clinical outcomes at 6 months, including ACS and STEMI patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Initial reports have been very promising, and published series have presented procedural success rates with this device of around 94% with periprocedural MI rates of 2 and 7% . Clinical follow‐up in these series was limited to 6 months with MACE rates of 10% in the initial experience , and 6% in a larger all‐comer registry .…”

Section: Discussionmentioning

confidence: 99%

“…The dedicated TRYTON Side‐Branch Stent™ (TRYTON Medical, Durham, NC) , used in conjunction with a conventional stent, intends to simplify a more technically demanding conventional culotte stenting procedure, by maintaining similar SB scaffolding while simultaneously improving branch access. Favorable acute clinical, angiographic and optical coherence tomography (OCT) results after TRYTON stenting have been reported, as well as 6‐month clinical and angiographic outcomes . We performed an in‐depth multimodality follow‐up analysis to understand better the complex interplay of device characteristics, stenting technique, healing processes, and hemodynamic and clinical outcome.…”

Section: Introductionmentioning

confidence: 99%

Healing responses after bifurcation stenting with the dedicated TRYTON side‐branch stent™ in combination with XIENCE‐V™ stents: A clinical, angiography, fractional flow reserve, and optical coherence tomography study: The PYTON (Prospective evaluation of the TRYTON side‐branch stent™ with an additional XIENCE‐v™ everolimus‐eluting stent in coronary bifurcation lesions) study

Dubois¹,

Adriaenssens

Ughi

et al. 2012

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Both these registries show that the treatment of bifurcation lesions with a dedicated Tryton stent is safe and feasible, with good technical and procedural success and low major adverse cardiac events at 6-month clinical follow-up [11].…”

Section: Resultsmentioning

confidence: 96%

Dedicated Tryton Side Branch Stents used in the treatment of coronary bifurcation lesions

Pleva¹,

Jonszta²,

Kukla³

et al. 2014

Cor Vasa

View full text Add to dashboard Cite

c o r e t v a s a 5 6 ( 2 0 1 4 ) e 4 7 8 -e 4 8 5 Tryton Side Branch Stent MS-CT coronarography a b s t r a c t Introduction: Coronary bifurcation lesions account for 15-20% of all percutaneous coronary interventions.Dedicated bifurcation stents have recently been introduced with the aim to simplify treatment and improve early and late outcomes following stenting of bifurcation lesions.The purpose of our study was to assess the safety and effectiveness of the Tryton dedicated side branch stent at a 6-month clinical and angiography follow-up. Methods: Forty-two patients with bifurcation lesions were included in our study. The primary endpoint was a 6-month MACE and angiographic stent patency was also evaluated by MS-CT coronarography. Results: Twenty-two patients (52.38%) were treated for acute coronary syndromes, 39 (92.85%) lesions were ''true bifurcations''. The 6-month clinical follow-up was performed in all patients.The 6-month MACE rate (cardiac death, myocardial infarction and target lesion revascularization) was 9.52% (95% CI: 2.66-22.62%); of these one patient (2.38%; 95% CI: 0.06-12.57%) died intensity projection; PCI, percutaneous coronary intervention; MACE, major adverse cardiovascular events; ISR, in-stent restenosis; TVR, target vessel revascularization; LM, left main stem; LAD, left anterior descending artery; RD, diagonal branch; LCx, left circumflex artery; OM, obtuse marginal branch; RCA, right coronary artery; PDA, posterior descending artery; SB, side branch; RAO, right anterior oblique view; LAO, left anterior oblique view.

show abstract

Six‐month clinical follow‐up of the tryton side branch stent for the treatment of bifurcation lesions

Abstract: In a real world the use of the Tryton Sidebranch stent is associated with good procedural safety and angiographic success rate and acceptable outcome at six months of follow-up.

Cited by 31 publications

References 41 publications

Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

Six-month clinical outcomes of the Tryton Side Branch Stent for the treatment of bifurcation lesions

Dedicated Tryton Side Branch Stents used in the treatment of coronary bifurcation lesions

Contact Info

Product

Resources

About